Novo Nordisk's controlling shareholder plans to invest about $35 billion by 2030
Reuters
Published Feb 12, 2024 06:44AM ET
(Reuters) -Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk (NYSE:NVO), plans to invest about $35 billion by 2030, CEO Kasim Kutay told Reuters in an interview on Monday.
Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030, Kutay said.
The company, the investment arm of the Novo Nordisk Foundation, has 77% of voting shares in Novo Nordisk that makes the blockbuster obesity drug Wegovy and diabetes treatment Ozempic.
Novo Holdings also has controlling stakes in industrial enzymes maker Novonesis, formerly known as Novozymes (OTC:NVZMY), and manages a portfolio of 160 companies.
Its portfolio comprises investments across life sciences and capital investments in equities, fixed-income assets, and real estate. Kutay said dividend payments from Novo Nordisk, boosted by the popularity of Ozempic and Wegovy, allowed it to reinvest.
The Financial Times first reported on Novo Holdings' investment plans.
The move comes soon after Novo Holdings said last week it would buy key manufacturing subcontractor Catalent (NYSE:CTLT) for $16.5 billion to boost Wegovy output.
Earlier this month, the company also said it was investing in Indian private hospital chain Manipal Hospitals, as it seeks to tap into the growing market potential in Asia.
Kutay on Monday added that India was a core focus for Novo Holdings' overall Asia strategy, and that it has invested in several companies in the country.
For Novo Holdings, which invests in life science companies and had assets of 108 billion euros ($115.86 billion) at end-2022, its recent investment in India was its largest in Asia to date.
Kutay added that future investments will be focused on countries in Asia, Europe, and North America, and that there were currently no planned investments in the Africa region.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.